[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postoperative-healing-after-endoscopic-nasal-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postoperative-healing-after-endoscopic-nasal-surgery":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100647874","phase-2-triamcinolone-nanocapsules-after-endoscopic-nasal-surgery-100647874",false,"NCT07714525","Triamcinolone Nanocapsules After Endoscopic Nasal Surgery","Clinical Evaluation of Triamcinolone Acetonide-loaded Nanoparticles For Nasal Postoperative Application","Inclusion Criteria\n\n* Adults aged 18 to 60 years.\n* Patients scheduled to undergo one of the following procedures:\n* Functional endoscopic sinus surgery\n* Endoscopic turbinoplasty\n* Endoscopic septoplasty\n* Diagnosis of chronic rhinosinusitis and\u002For nasal polyps requiring surgical intervention.\n* Ability and willingness to provide written informed consent.\n* Ability and willingness to comply with study treatment and scheduled follow-up visits.\n\nExclusion Criteria\n\n* Known hypersensitivity to triamcinolone acetonide.\n* Known hypersensitivity to any component of the polymeric nanocapsule formulation.\n* Systemic contraindication to corticosteroid therapy.\n* Active severe nasal or sinonasal infection at the time of enrollment or treatment.\n* Pregnancy or breastfeeding, if excluded in the approved protocol.\n* Uncontrolled diabetes mellitus, if corticosteroid exposure is considered clinically relevant.\n* Immunosuppression or use of immunosuppressive therapy.\n* Recent use of systemic or intranasal corticosteroids within the protocol-defined washout period.\n* Participation in another clinical trial.\n* Any medical or psychiatric condition that may interfere with informed consent, study treatment, or follow-up.\n* Inability to complete the required questionnaires or follow-up visits.","ALL","18 Years","60 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This randomised, single-masked, parallel-group clinical trial will evaluate the efficacy and safety of a topical triamcinolone acetonide-loaded polymeric nanocapsule formulation for postoperative care following endoscopic nasal surgery.\n\nParticipants will receive either the investigational triamcinolone acetonide-loaded nanocapsule formulation or standard normal saline nasal irrigation. Postoperative nasal healing, inflammation, patient-reported sinonasal symptoms, postoperative complications, and corticosteroid-related adverse effects will be compared between the two groups.",[27,28,29],"Chronic Rhinosinusitis (CRS)","Nasal Polyps","Postoperative Healing After Endoscopic Nasal Surgery",[31,32,33,34],"Triamcinolone acetonide","Nanocapsules","Polymeric nanocapsules","Endoscopic nasal surgery","RECRUITING","2026-07-24",{"date":38,"type":39},"2026-07-27","ACTUAL",{"date":41,"type":39},"2026-05-01",{"date":43,"type":21},"2027-06-01",{"name":45,"class":46},"Deraya University","OTHER"]